More Articles Back to Article
Aslan's acute myeloid leukemia candidate shows potential
Pre-clinical data published in the Haematologica Journal showed Aslan Pharmaceuticals' experimental candidate ASLAN003 as having potential to treat acute myeloid leukemia. The company is studying future development plans for the drug after the completion of a Phase IIa trial for ASLAN003. Seeking Alpha (11/22)
Read full article now.
Don't Miss Out!
Get your weekly Breakfast Briefing eNewsletter, filled with news, trends, and vital information from DIA!